NEWS HIGHLIGHTSMedia Articles Related to Avita (Tretinoin)
isotretinoin, Sotret, Claravis, Amnesteem, (Accutane is no longer available)
Source: MedicineNet Boils Specialty [2008.04.16]
Title: isotretinoin, Sotret, Claravis, Amnesteem, (Accutane is no longer available)
Category: Medications
Created: 12/31/1997
Last Editorial Review: 4/16/2008
Basilea's Toctino(R) Receives Marketing Authorization In Canada
Source: Dermatology News From Medical News Today [2009.11.18]
Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has obtained regulatory approval from Health Canada. "We are delighted that Health Canada has approved the use of Toctino for patients with severe chronic hand eczema unresponsive to potent topical steroids.
Published Studies Related to Avita (Tretinoin)
Tolerability of high-dose topical tretinoin: the Veterans Affairs Topical Tretinoin Chemoprevention Trial. [2009.10]
BACKGROUND: Topical tretinoin is a medication commonly used for acne that has potential application in the long-term treatment of photodamaged skin. However, there are few published data regarding the tolerability of high-dose tretinoin with long-term use. OBJECTIVES: To assess the long-term tolerability of tretinoin 0.1% cream... CONCLUSIONS: Overall, the tolerability level of topical tretinoin was high in this study population, with almost 40% of the tretinoin group reporting no side-effects, and the majority (67%) tolerating at least once-daily dosing at 6-month follow-up. High-dose topical tretinoin is feasible for long-term use in this population.
Benefits of using a hydroquinone/tretinoin skin care system in patients undergoing intense pulsed light therapy for photorejuvenation: a placebo-controlled study. [2009.09]
A hydroquinone/tretinoin (HQ/tret) skin care system designed for use with non-surgical facial rejuvenation procedures has recently become available. In this observer-masked study, 36 patients with moderate-to-severe wrinkling of the skin around the eyes and lips were randomly assigned to use either the 4% hydroquinone/0.05% tretinoin skin care system or placebo products, each day for 90 days...
Quality of life in the actinic neoplasia syndrome: The VA Topical Tretinoin Chemoprevention (VATTC) Trial. [2009.08]
BACKGROUND: Keratinocyte carcinomas (KCs) are the most common malignancies of the skin. As lesions have a low mortality rate, understanding quality-of-life (QoL) factors is necessary in their management. OBJECTIVE: To assess QoL and associated patient characteristics in those with a history of keratinocyte carcinomas... CONCLUSIONS: A history of ever use of 5-FU and present AKs was strongly associated with worse QoL. We find it more useful to consider these patients as having the chronic condition "actinic neoplasia syndrome," whose burden may be best measured by factors other than their history of KCs.
Comparative efficacy and safety results of two topical combination acne regimens. [2009.07]
Combination therapy has become the standard for the management of acne, particularly for moderate-to-severe cases... Both treatment regimens were well-tolerated.
Reappraising the phototoxicity of tretinoin: a report of four controlled clinical trials. [2009.06]
BACKGROUND: Retinoids are photoreactive molecules found in skin and retinal tissue. The use of retinoids in pharmacologic doses, applied topically, raises the potential of phototoxicities. Recent review articles and current US drug labeling indicate that tretinoin is a phototoxin. In developing a new formulation of topical all-trans-retinoic acid (tretinoin), formal testing of dermal photoreactions was therefore undertaken... CONCLUSION: The findings in these studies are consistent with previous studies of tretinoin in various formulations, and support the conclusion that tretinoin appears to be neither phototoxic nor photoallergenic in vivo.
Clinical Trials Related to Avita (Tretinoin)
Single-Dose Postpartum Vitamin A Supplementation of Mothers and Neonates [Active, not recruiting]
The ZVITAMBO PROJECT is testing whether giving mothers and infants a single large dose of
vitamin A during the immediate post partum period will reduce:
1. Infant Mortality Can oral administration of a single 50,000 IU dose of vitamin A to
newborn infants, a single 400,000 IU dose of vitamin A given to their lactating mothers,
or supplementation of both the mother and infant during the immediate post partum period
reduce infant mortality by at least 30%?
2. Mother to Child HIV transmission during breast feeding Can oral administration of a
single large dose of vitamin A given during the immediate post partum period to HIV
seropositive lactating women and/or their babies reduce HIV transmission via breast
feeding by at least 30%?
3. Sexually transmitted HIV infection of post partum women Can a single 400,000 IU dose of
vitamin A given during the immediate post partum period to HIV seronegative women reduce
their likelihood of becoming HIV infected during the post partum year by at least 25%?
4. Infant feeding in the context of HIV: An operational research study was initiated
mid-way through the trial to determine how UNAIDS Guidelines on infant feeding in the
context of HIV could be effectively implemented and to measure the impact of such a
program on infant feeding practices and postnatal HIV transmission.
Substudies:
Random subsamples of maternal and infant blood were evaluated for anemia and iron status to
determine the effect of vitamin A on hematopoiesis and serum and breast milk retinol
(mothers) and modified relative dose response test (infants) to determine the effect of
vitamin A on vitamin A status.
A subsample of maternal and infant blood samples were evaluated for the presence of HLA-E,
HLA-G, and TAP polymorphisms and their relation to prevalent HIV infection in mothers and
risk of mother to child transmission.
Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis [Not yet recruiting]
In populations with high prevalence of latent tuberculosis infection (LTBI), malnutrition
(PEM) may influence incident rates of TB. PEM and specific micronutrient deficiencies
compromise cell mediated immunity (CMI) and increase susceptibility to, or severity of
infections. Vitamin A supplementation significantly reduces all-cause child mortality. The
mechanism of the benefits of supplementation on clinical outcomes is largely unknown, but is
likely to be related to an influence on the immune system. Vitamin A supplementation
promotes lymphogenesis and induces a higher proportion of CD4 naïve T-cells in children.
Most cases of LTBI that progress to active disease are vitamin A deficient. Vitamin A
deficiency is common in most TB endemic countries. At the MRC, 32% of TBCC contacts were
vitamin A deficient.
Hypothesis:
The investigators plan to test the hypotheses: that supplementation with vitamin A will
affect the magnitude and quality of immune responses to mycobacterial antigens and
progression to clinical disease.
Vitamin A and Very Low Birthweight Babies (VitAL) [Recruiting]
Vitamin A is important for the development of healthy eyes and lungs. Very low birth weight
premature babies have low body stores of vitamin A and are prone to diseases of the eye and
lungs. Previous work has shown that intramuscular (IM) vitamin A reduces the number of
babies who require prolonged oxygen therapy, and may also reduce the number of babies
affected by retinopathy of prematurity (ROP)). There is also some evidence that the
conjunctiva shows signs of deficiency of vitamin A in premature infants, particularly those
who develop ROP. Our own work here in Glasgow suggests that, compared to babies born at
full term, premature babies' eyes are less sensitive to light and we believe that this may
reflect shortage of vitamin A in the eye. This study will examine the effects upon the eye
of giving extra intramuscular vitamin A to very low birth weight, premature infants. We
will also measure blood levels of vitamin A and calculate liver stores of this nutrient.
Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission [Completed]
HIV infected individuals with vitamin A deficiency may be more likely to transmit the virus
to others than HIV infected individuals who have normal levels of vitamin A. The presence of
HIV DNA in vaginal secretions may indicate a greater risk for transmission of HIV to others.
The purpose of this study is to determine if taking vitamin A decreases the level of HIV DNA
in vaginal secretions.
Trial of the Impact of Vitamin A on Maternal Mortality [Recruiting]
Main objectives: To evaluate the impact of weekly vitamin A supplementation (VAS) to women of
reproductive age (15-45 years) on maternal mortality in rural Ghana, and to compare this with
the impact on overall mortality.
Hypotheses:
1. Weekly supplementation with vitamin A (7000 µg retinol equivalent [RE]) to reproductive
age women will reduce maternal deaths by 33%.
2. This impact will be achieved by reductions in both pregnancy-related and
non-pregnancy-related deaths.
3. There will be a reduction in non-maternal deaths, similar in size to that in maternal
non-pregnancy related deaths.
Outcome measures: Maternal mortality rate, and overall mortality rate. Deaths will be
identified through monthly demographic surveillance, and classified as maternal
(pregnancy-related, non-pregnancy-related) or non-maternal using verbal autopsies.
|
